Article Details

Cell therapy biotech Affini-T gets $175M; KRAS is lead genomic cancer target - MedCity News

Retrieved on: 2022-03-23 02:47:12

Tags for this article:

Click the tags to see associated articles and topics

Cell therapy biotech Affini-T gets $175M; KRAS is lead genomic cancer target - MedCity News. View article details on hiswai:

Excerpt

Affini-T goes further, employing synthetic biology to engineer “switch receptors” that convert the immunosuppressive signals from the tumor into ...

Article found on: medcitynews.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up